Company: SCLXW
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001193125-25-172703
Chunk: 506

Company: Scilex Holding Co
Filing Date: 2025-08-04
Form: S-1
Chunk 506
---
 the Company shall have any further liability or obligations thereunder. In consideration of Endeavor assuming the payment obligation of the Company in respect of the FSF Deposit, Endeavor will not be responsible for making any payment to the Company for (i) the product already delivered as of the date of such agreement in an amount of approximately $ 13.2 million and (ii) the Additional Product. Pursuant to the terms of the Satisfaction Agreement, if the Company fails to fully deliver the Additional Product by December 31, 2024, the Company shall be liable to Endeavor for liquidated damages in the amount of $ 20,000,000 . In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit.

The following table provides a summary of the changes in the balance and the estimated fair value of the FSF Deposit (in thousands):

|                                                                       |     | December 31,2024 |         |   |
|:----------------------------------------------------------------------|:----|:-----------------|--------:|:--|
| Beginning Balance as of June 11, 2024                                 |     | $                |  10,000 |   |
| Change in fair value of FSF Deposit                                   |     |                  |   4,690 |   |
| Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit |     |                  |  (1,690 | ) |
| Repayment of FSF Deposit                                              |     |                  | (13,000 | ) |
| Ending Balance as of December 31, 2024                                |     | $                |       — |   |

Tranche B Notes

On October 8, 2024, the Company entered into the Tranche B Securities Purchase Agreement with the Tranche B Investors and Oramed to refinance a portion of the Oramed Note and pay off certain other indebtedness of the

<div align='center'>F-32</div>

Company. Pursuant to the Tranche B Securities Purchase Agreement, the Company agreed to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders: (i) the Tranche B Notes, which notes will mature on the two-yearanniversary of the issuance date and will be convertible into shares of Common Stock at a conversion price equal to $ 38.15per share (which was automatically reduced to $ 36.40per share of Common Stock subsequent to the December 202